Plasmapheresis Eliminates the Negative Impact of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery

1] Departments of Pediatrics and Neurology, The Ohio State University and Nationwide Children's Hospital, Columbus, OH, USA, [2] Centers for Gene Therapy and Vaccines and Immunity at The Research Institute at Nationwide Children's Hospital, Columbus, OH. [3] Integrated Biomedical Science Graduate Program, College of Medicine, The Ohio State University, Columbus, OH.
Molecular Therapy (Impact Factor: 6.23). 10/2013; 22(2). DOI: 10.1038/mt.2013.244
Source: PubMed


Duchenne muscular dystrophy (DMD) is a monogenic disease potentially treatable by gene replacement. Use of recombinant adeno-associated virus will ultimately require a vascular approach to broadly transduce muscle. We tested the impact of pre-existing AAV antibodies on micro-dystrophin expression following vascular delivery to non-human primates. Rhesus macaques were treated by isolated limb perfusion via a fluoroscopically guided catheter. In addition to serostatus stratification, the animals were placed into one of three immune suppression groups: no immune suppression, prednisone, and triple immune suppression (prednisone, tacrolimus and mycophenolate mofetil). The animals were analyzed for transgene expression at 3 or 6 months. Micro-dystrophin expression was visualized in AAVrh.74 sero-negative animals (mean 48.0% ± 20.8) that was attenuated in sero-positive animals (19.6 ± 18.7%). Immunosuppression did not affect transgene expression. Importantly, removal of AAV binding antibodies by plasmapheresis in AAV sero-positive animals resulted in high level transduction (60.8 ± 18.0%), which is comparable to that of AAV sero-negative animals (53.7 ± 7.6%). While non-pheresed sero-positive animals demonstrated significantly lower transduction levels (10.1 ± 6.0%). These data support the hypothesis that removal of AAV binding antibodies by plasmapheresis permits successful and sustained gene transfer in the presence of pre-existing immunity (natural infection) to AAV.Molecular Therapy (2013); doi:10.1038/mt.2013.244.

Download full-text


Available from: Louise Rodino-Klapac, Apr 17, 2015
34 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Overexpression of GALGT2 in skeletal muscle can stimulate the glycosylation of α dystroglycan and the upregulation of normally synaptic dystroglycan-binding proteins, some of which are dystrophin and laminin α2 surrogates known to be therapeutic in forms of muscular dystrophy. Here, we describe for the first time vascular delivery of GALGT2 gene therapy in a large animal model, the rhesus macaque. Recombinant adeno associated virus, rhesus serotype 74 (rAAVrh74), was used to deliver GALGT2 via the femoral artery to the gastrocnemius muscle using an isolated focal limb perfusion method. GALGT2 expression averaged 44±4% of myofibers after treatment in macaques with low pre-existing anti-rAAVrh74 serum antibodies, and expression was reduced to 9±4% of myofibers in macaques with high pre-existing rAAVrh74 immunity (p<0.001, n=12 per group). This was the case regardless of the addition of immunosuppressants, including prednisolone, tacrolimus and mycophenolate mofetil. GALGT2-treated macaque muscles showed increased glycosylation of α dystroglycan and increased expression of dystrophin and laminin α2 surrogate proteins, including utrophin, plectin1, agrin and laminin α5. These experiments demonstrate successful transduction of rhesus macaque muscle with rAAVrh74.MCK.GALGT2 after vascular delivery and induction of molecular changes thought to be therapeutic in several forms of muscular dystrophy.Molecular Therapy (2013); doi:10.1038/mt.2013.246.
    Molecular Therapy 10/2013; 22(4). DOI:10.1038/mt.2013.246 · 6.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Duchenne muscular dystrophy (DMD) is an inherited, progressive muscle wasting disorder caused by mutations in the dystrophin gene. An increasing variety of approaches are moving towards clinical testing that all aim to restore dystrophin production and to enhance or preserve muscle mass. Gene therapy methods are being developed to replace the defective dystrophin gene or induce dystrophin production from mutant genes. Stem cell approaches are being developed to replace lost muscle cells while also bringing in new dystrophin genes. This review summarizes recent progress in the field with an emphasis on clinical applications.
    06/2014; 2(2):102-112. DOI:10.1007/s40124-014-0044-x
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently adeno-associated virus (AAV) became the first clinically approved gene therapy product in the western world. To develop AAV for future clinical application in a widespread patient base, particularly in therapies which require intravenous (i.v.) administration of vector, the virus must be able to evade pre-existing antibodies to the wild type virus. Here we demonstrate that in mice, AAV vectors associated with extracellular vesicles (EVs) can evade human anti-AAV neutralizing antibodies. We observed different antibody evasion and gene transfer abilities with populations of EVs isolated by different centrifugal forces. EV-associated AAV vector (ev-AAV) was up to 136-fold more resistant over a range of neutralizing antibody concentrations relative to standard AAV vector in vitro. Importantly in mice, at a concentration of passively transferred human antibodies which decreased i.v. administered standard AAV transduction of brain by 80%, transduction of ev-AAV transduction was not reduced and was 4000-fold higher. Finally, we show that expressing a brain targeting peptide on the EV surface allowed significant enhancement of transduction compared to untargeted ev-AAV. Using ev-AAV represents an effective, clinically relevant approach to evade human neutralizing anti-AAV antibodies after systemic administration of vector.
    Biomaterials 06/2014; 35(26). DOI:10.1016/j.biomaterials.2014.05.032 · 8.56 Impact Factor
Show more